Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.

Saruwatari K, Ikeda T, Saeki S, Shingu N, Imamura K, Komatu T, Ushijima S, Maruyama H, Kashiwabara K, Tomita Y, Ichiyasu H, Fujii K, Sakagami T.

Anticancer Res. 2019 Feb;39(2):923-931. doi: 10.21873/anticanres.13195.

PMID:
30711977
2.

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.

Aiko N, Shimokawa T, Miyazaki K, Misumi Y, Agemi Y, Ishii M, Nakamura Y, Yamanaka T, Okamoto H.

BMC Cancer. 2018 Oct 22;18(1):1012. doi: 10.1186/s12885-018-4911-7.

3.

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL.

J Clin Oncol. 2017 Apr 1;35(10):1070-1077. doi: 10.1200/JCO.2016.69.7144. Epub 2017 Jan 23.

PMID:
28113019
4.

Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.

Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q.

Thorac Cancer. 2016 Nov;7(6):648-654. doi: 10.1111/1759-7714.12379. Epub 2016 Sep 1.

5.

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.

Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.

Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22.

6.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
7.

Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).

Zhu Q, Sun Y, Cui Y, Ye K, Yang C, Yang D, Ma J, Liu X, Yu J, Ge H.

Oncotarget. 2017 Feb 21;8(8):13304-13311. doi: 10.18632/oncotarget.14515.

8.

Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.

Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Chih-Hsin Yang J, Yu CJ.

Oncologist. 2017 Sep;22(9):1075-1083. doi: 10.1634/theoncologist.2016-0331. Epub 2017 May 15.

10.

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.

Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.

J Clin Pharm Ther. 2015 Dec;40(6):661-71. doi: 10.1111/jcpt.12332. Epub 2015 Nov 17.

PMID:
26573867
11.

Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.

Chang CH, Lee CH, Ko JC, Chang LY, Lee MC, Wang JY, Yu CJ.

Cancer Med. 2017 Jul;6(7):1563-1572. doi: 10.1002/cam4.1121. Epub 2017 Jun 22.

13.

Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.

Fiala O, Pesek M, Finek J, Racek J, Minarik M, Benesova L, Bortlicek Z, Sorejs O, Kucera R, Topolcan O.

Neoplasma. 2016;63(3):471-6. doi: 10.4149/318_151001N512.

PMID:
26952513
14.

Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.

Li MX, He H, Ruan ZH, Zhu YX, Li RQ, He X, Lan BH, Zhang ZM, Liu GD, Xiao HL, Wu Y, Zhu B, Wang G, Yang ZZ.

BMC Cancer. 2017 Apr 4;17(1):245. doi: 10.1186/s12885-017-3165-0.

15.

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.

Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS.

Korean J Intern Med. 2015 Nov;30(6):891-8. doi: 10.3904/kjim.2015.30.6.891. Epub 2015 Oct 30.

16.

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.

Jiang Y, Zhang J, Huang J, Xu B, Li N, Cao L, Zhao M.

BMC Pulm Med. 2018 Nov 20;18(1):171. doi: 10.1186/s12890-018-0734-1.

17.

Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.

Sekine A, Satoh H, Iwasawa T, Tamura K, Hayashihara K, Saito T, Kato T, Arai M, Okudela K, Ohashi K, Ogura T.

Med Oncol. 2014 Oct;31(10):228. doi: 10.1007/s12032-014-0228-9. Epub 2014 Sep 11. Erratum in: Med Oncol. 2015 May;32(5):166.

PMID:
25208818
18.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
19.

Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.

Yang WC, Xiao F, Shih JY, Ho CC, Chen YF, Tseng HM, Chen KY, Liao WY, Yu CJ, Yang JC, Kuo SH, Cheng JC, Yang PC, Hsu FM.

Radiother Oncol. 2018 Feb;126(2):368-374. doi: 10.1016/j.radonc.2017.10.010. Epub 2017 Oct 27.

PMID:
29111173

Supplemental Content

Support Center